ProtAffin Biotechnologie

Austria
Greifenburg, Carinthia, Austria, 8020

Company profile

ProtAffin Biotechnologie company profile

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

Business identity

Contact email
[email protected]
Phone number
+43 316 382 541
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2005-01-01, Year

Headquarters

Postal code
8020
Country code
AT
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$7.1M
Last funding
Series A / $2M / 2008-01-21
Last equity funding
Series A / $2M
Investors
3
Lead investors
1

Founders and investors

Lead investors

Aescap Venture

Investors

Aescap VentureHaller CapitalZcube